Merck To Stop Making COVID-19 Vaccines After Failed Trials

In a major setback US pharma giant Merck has announced that it will stop making its COVID-19 vaccines after failed clinical trials to generate a strong immune response.

Merck To Stop Making COVID-19 Vaccines After Failed Trials

US pharma giant Merck has scrapped two coronavirus vaccine candidates after they failed to produce an adequate immune response in early trials, the company announced Monday.

The results were “disappointing, and a bit of a surprise,” Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories, told Bloomberg.

The studies haven’t yet been published in a peer-reviewed journal to be scrutinized.

Merck said it would now focus on advancing two experimental treatments for COVID-19 that are in late stage development.

Subscribe to GreatGameIndia

Enter your email address to subscribe to GGI and receive notifications of new posts by email.

“In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets,” Kartsonis told the Wall Street Journal.

For latest updates on the outbreak check out our Coronavirus Coverage.

Send in your tips and submissions by filling out this form or write to us directly at the email provided. Join us on WhatsApp for more intel and updates.

We need your support to carry on our independent and investigative research based journalism on the Deep State threats facing humanity. Your contribution however small helps us keep afloat. Kindly consider supporting GreatGameIndia.

Support GreatGameIndia


  1. I can’t take Merck announcement at face value. It may be due to very negative effect on antibody formulation. In stead of neutralizing one (NAb), it may generate insted non-neutralizing antibodies (n-NAb), or Binding antibodies, leading to cytokine storm and death. Overall, where is the command center of this global operation of population control? This must be destroyed.

Leave a Reply